Thursday, 21 August 2003
This presentation is part of : Late Onset Schizophrenia: New Wine in Old Bottle

S082-004 The Impact of Raloxifene on Cognitive Functioning in Postmenopausal Women with Psychosis

Jiahui Wong, Department of Psychiatry, Mount Sinai Hospital, Toronto, ON, Canada and Mary Seeman, Schizophrenia Research, The Centre for Addiction and Mental Health, Clarke Site, Toronto, ON, Canada.

Objective: To determine the impact of raloxifene, a selective estrogen receptor modulator on cognitive functions in postmenopausal women with schizophrenia.

Method: Raloxifene was used as an antipsychotic adjunct in a double blind, randomized, crossover study (8 weeks 60 mg/d raloxifene; 8 weeks placebo). Measurements: The California Verbal Learning Test, the Positive and Negative Syndrome Scale, and the Extrapyramidal Side Effect Scale were administered at baseline and every 4 weeks for the duration of the study.

Results: Descriptive statistics will be presented. Initial data show a trend for improvement in cognitive functioning on test measures with practice, and a trend for further improvement with raloxifene. Symptoms of schizophrenia remained unchanged.

Conclusions: Selective estrogen receptor modulators may prove to be safe and potentially effective enhancers of cognitive function in schizophrenia.

Back to S082 Late Onset Schizophrenia: New Wine in Old Bottle
Back to The Eleventh International Congress